SEC Form 4 · accession 0000930413-17-003701
ENZO BIOCHEM INC · ENZ
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Dov Perlysky
Director
Period of report
Oct 31, 2017
Accepted (ET)
Nov 2, 2017 · 8:00 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000316253
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Oct 31, 2017 | M | 59,455 | $2.88 | A | 684,237 | D | |
| Common StockF1,F2 | Oct 31, 2017 | S | 42,000 | $9.81 | D | 642,237 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock option (to acquire common stock) | $2.88 | Oct 31, 2017 | M | 59,455 | D | Jan 17, 2014 | Jan 17, 2018 | Common Stock | 59,455 | 239,632 | D |
Explanation of responses
- F1Represents shares sold to cover the exercise price of the Stock Options and shares sold to satisfy reporting person's tax obligations.
- F2The sale price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.80 to $9.93, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.